Related Experiment Video
Updated: Jul 2, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Emerging links between cell competition and Alzheimer's disease
Dina S Coelho1, Eduardo Moreno2
1Cell Fitness Laboratory, Champalimaud Centre for the Unknown, Av. Brasília., 1400-038 Lisbon, Portugal.
Journal of Cell Science
|July 3, 2019
Summary
Cell competition, a process where less fit neurons are eliminated, shows promise in protecting against Alzheimer's disease (AD) by delaying cognitive decline. This mechanism offers a potential new therapeutic avenue for neurodegenerative disorders.
Area of Science:
- Neuroscience
- Cell Biology
- Genetics
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss and cognitive decline.
- Excessive amyloid-beta (Aβ) accumulation triggers pathological events leading to neuronal death, but mechanisms remain incompletely understood.
- Current treatments for AD are limited, highlighting the urgent need for novel therapeutic strategies.
Purpose of the Study:
- To review the molecular mechanisms of cell competition.
- To explore the relevance of neuronal competition in the nervous system.
- To discuss the potential of cell competition as a therapeutic strategy for Alzheimer's disease.
Main Methods:
- Review of existing literature on cell competition mechanisms.
- Analysis of genetic triggers and effectors involved in cell elimination.
- Discussion of competitive interactions in the context of AD pathogenesis.
Main Results:
- Cell competition can protect against AD by eliminating less fit, Aβ-damaged neurons in a fly model.
- The loss of damaged neurons via fitness comparison delays cognitive decline and motor disability.
- This process highlights the beneficial role of eliminating compromised neurons.
Conclusions:
- Cell competition is an emerging mechanism with protective potential against neurodegenerative diseases like AD.
- Understanding neuronal competition offers new therapeutic avenues for treating neurological disorders.
- Further research into fitness-based neuronal selection may yield novel treatments for AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...